Assenagon Asset Management S.A. Editas Medicine, Inc. Transaction History

Assenagon Asset Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$4.67 - $7.28 $157,393 - $245,357	-33,703 Reduced 59.09%	23,330 $108,000
Q1 2024 Apr 24, 2024	BUY	$7.03 - $11.07 $131,777 - $207,507	18,745 Added 48.96%	57,033 $423,000
Q4 2023 Jan 17, 2024	BUY	$6.25 - $11.11 $8,650 - $15,376	1,384 Added 3.75%	38,288 $387,000
Q3 2023 Nov 06, 2023	BUY	$6.92 - $9.31 $255,375 - $343,576	36,904 New	36,904 $287,000
Q1 2023 Apr 18, 2023	BUY	$7.03 - $11.53 $1.18 Million - $1.94 Million	167,981 New	167,981 $1.22 Million
Q2 2022 Jul 27, 2022	SELL	$9.99 - $21.35 $2.33 Million - $4.98 Million	-233,487 Closed	0 $0
Q1 2022 Apr 25, 2022	BUY	$14.08 - $27.63 $3.29 Million - $6.45 Million	233,487 New	233,487 $4.44 Million
Q1 2020 Apr 17, 2020	SELL	$14.88 - $32.78 $399,661 - $880,438	-26,859 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$19.49 - $32.63 $523,481 - $876,409	26,859 New	26,859 $795,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.